VYGR supply chain intelligence for Voyager Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CELG-RI | CELG-RI | 72% | and EO 14070, Continuing to Strengthen Americans’ Access to Affordable, Quality Health Coverage) where were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from VYGR graph: and EO 14070, Continuing to S… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are un… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act a… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws gov… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VYGR graph: d hazardous substances, including… |
| SNYNF | Sanofi | 72% | d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws gov… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NEUROCRINE | NEUROCRINE | 95% | For the three months ended March 31, 2026, we recognized $1.3 million of collaboration revenue from the 2023 Neurocrine Collaboration Agreement, $0.1 million of collaboration revenue from the 2019 Ne… |
| NVS | Novartis AG | 92% | For the three months ended March 31, 2026, we recognized $1.2 million of collaboration revenue in connection with the 2023 Novartis Collaboration Agreement |
| NVS | Novartis AG | 92% | Reciprocal relationship from NVS graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from NVS graph: Reciprocal relationship from VYGR graph: For the three months ended March 31, … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from VYGR graph: and EO 14070, Continuing to Strengthen Americans’ Access to Affordable, Quality Health Coverage) where were design… |
| CELG-RI | CELG-RI | 72% | and EO 14070, Continuing to Strengthen Americans’ Access to Affordable, Quality Health Coverage) where were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, … |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a s… |
| MGTX | MeiraGTx Holdings plc | 72% | Reciprocal relationship from MGTX graph: acture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a QC hub performing advanced biochemical quality contro… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act a… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws gov… |
| NVSEF | Novartis AG | 72% | pon certain terminations for cause by Novartis, the licenses granted by the Company to Novartis under the 2022 Novartis Agreement shall become irrevocable and perpetual, and all milestone payments an… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from NVSE… |
| SNYNF | Sanofi | 72% | d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws gov… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VYGR graph: d hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VYGR-DEBT-13482 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2015-12-31. |
| VYGR-DEBT | Debt stack $34.6M | 90% | Market cache reports total debt of $34.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VYGR-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 135 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 100.00 | 2 | |
| ONC | BeOne Medicines AG | 100.00 | 2 | |
| MPLT | MapLight Therapeutics, Inc. | 100.00 | 2 | |
| SLNO | Soleno Therapeutics, Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | ['customer', 'supplier'] |
| PTCT | PTC Therapeutics, Inc. | 100.00 | 2 | |
| NBIX | Neurocrine Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SGIOF | Shionogi & Co., Ltd. | 100.00 | 2 | |
| SLDB | Solid Biosciences Inc. | 100.00 | 2 | |
| GANX | Gain Therapeutics, Inc. | 100.00 | 2 | |
| AARD | Aardvark Therapeutics, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| ETON | Eton Pharmaceuticals, Inc. | 100.00 | 2 | |
| STQN | Strategic Acquisitions, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 2 |